New psychoactive substances as adulterants of controlled drugs. A worrying phenomenon?

Drug Testing and Analysis

Volumn 6, Issue 7-8, 2014, Pages 819-824

  Giné, Claudio Vidal ^a   Espinosa, Iván Fornís ^a   Vilamala, Mireia Ventura ^a  

^a Asociacion Bienestar y Desarrollo   (Spain)

Author keywords

Adulteration; Controlled drugs; Illegal market; New psychoactive substances

Indexed keywords

AMINES; COMMERCE; CONTROLLED DRUG DELIVERY; DRUG PRODUCTS;

ADULTERATION; CATHINONE; CHEMICAL CLASS; CONTROLED DRUG; ILLEGAL MARKET; KETAMINE; NEW PSYCHOACTIVE SUBSTANCE; PHENETHYLAMINES; POTENTIAL RISKS; TRYPTAMINES;

CRIME;

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMINE; CATHINONE; COCAINE; CONTROLLED SUBSTANCE; KETAMINE; MESCALINE; METHAMPHETAMINE; PHENETHYLAMINE DERIVATIVE; PSYCHOTROPIC AGENT; TRYPTAMINE DERIVATIVE; DRUG; STREET DRUG;

ARTICLE; DRUG IMPURITY; DRUG MONITORING; EUROPEAN UNION; PRIORITY JOURNAL; CHEMISTRY; DRUG CONTAMINATION; DRUG CONTROL; SUBSTANCE ABUSE;

DRUG AND NARCOTIC CONTROL; DRUG CONTAMINATION; PHARMACEUTICAL PREPARATIONS; PSYCHOTROPIC DRUGS; STREET DRUGS; SUBSTANCE ABUSE DETECTION;

EID: 84904551845     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.1610     Document Type: Article

References (34)

1. F. Caudevilla-Gálligo, J. Riba, M. Ventura, D. González, M. Farré, M.J. Barbanoj, J.C. Bouso . 4-Bromo-2, 5-dimethoxyphenethylamine (2C-B): Presence in the recreational drug market in Spain, pattern of use and subjective effects. J. Psychopharmacol. 2012, 26, 1026.
2. M. Vevelstad, E.L. Øiestad, G. Middelkoop, I. Hasvold, P. Lilleng, G.J. Delaveris, T. Eggen, J. Mørland, M. Arnestad . The PMMA epidemic in Norway: Comparison of fatal and non-fatal intoxications. Forensic Sci. Int. 2012, 219, 151.
3. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Europol Joint Report on a New Psychoactive Substance: 4-Methylamphetamine. EMCDDA, Lisbon, 2012.
4. L. Knowles, J.A. Buxton, N. Skuridina, I. Achebe, D. Legatt, S. Fan, N. Yan Zhu, J. Talbot . Levamisole tainted cocaine causing severe neutropenia in Alberta and British Columbia. Harm Reduct. J. 2009, 6, 30.
5. N. Vanattou-Saïfoudine, R. McNamara, A. Harkin . Caffeine provokes adverse interactions with MDMA ("Ecstasy") and related psychostimulants: Mechanisms and mediators. Brit. J. Pharmacol. 2012, 167, 946.
6. M. Ventura, F. Caudevilla, C. Vidal, Grupo Investigadores SELECTO. Levamisole-adulterated cocaine: Potential clinical implications. Med. Clin. 2010, 136, 367.
7. N.Y. Zhu, D.F. Legatt, A.R. Turner . Agranulocytosis after consumption of cocaine adulterated with levamisole. Ann. Intern. Med. 2009, 150, 287.
8. P. Blanckaert, J. van Amsterdam, T.M. Brunt, J. van den Berg, F. van Durme, K. Maudens, J. van Bussel . 4-Methyl-amphetamine: A health threat for recreational amphetamine users. J. Psychopharmacol. 2013. DOI: 10.1177/0269881113487950
9. A.C. Parrot . Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity. Psychopharmacology (Berl) 2004, 173, 234.
10. T.M. Brunt, S. Rigter, J. Hoek, N. Vogels, P. van Dijk, RJ Niesink . An analysis of cocaine powder in the Netherlands: Content and health hazards due to adulterants. Addiction 2009, 104, 798.
11. N. Vogels, T.M. Brunt, S. Rigter, P. van Dijk, H. Vervaeke, R.J. Niesink . Content of ecstasy in the Netherlands: 1993-2008. Addiction 2009, 104, 2057.
12. M.G. Bossong, T.M. Brunt, J.P. Van Dijk, S.M. Rigter, J. Hoek, H.M. Goldschmidt, R.J. Niesink . mCPP: An undesired addition to the ecstasy market. J. Psychopharmacol. 2010, 24, 1395.
13. T.M. Brunt, R.J. Niesink . The drug information and monitoring system (DIMS) in the Netherlands: Implementation, results, and international comparison. Drug Test. Anal. 2011, 3, 621.
14. T.M. Brunt, A. Poortman, R.J. Niesink, W. van den Brink . Instability of the ecstasy market and a new kid on the block: Mephedrone. J. Psychopharmacol. 2011, 25, 1543.
15. C. Cole, L. Jones, J. McVeigh, A. Kicman, Q. Syed, M. Bellis . Adulterants in illicit drugs: A review of empirical evidence. Drug Test. Anal. 2011, 3, 89.
16. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Annual Report 2010. EMCDDA, Lisbon, 2010.
17. United Nations Office on Drugs and Crime. World Drug Report 2010. United Nations, Vienna, 2010.
18. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). 2012 National Report (2011 Data) to the EMCDDA by the Reitox National Focal Point: SPAIN: New development, trends and in-depth information on selected issues. EMCDDA, Lisbon, 2012.
19. M. Barriuso, I. Markez . El uso de ketamina en el País Vasco: De fármaco anestésico a droga de fiesta. Servicio Central de Publicaciones del Gobierno Vasco, Vitoria-Gasteiz, 2004.
20. Trans European Drug Information (TEDI). TEDI Trend Report. Available at: http://www.tediproject.org/uploads/trend_reports_file_1359936258.pdf [15 August 2013].
21. EcstasyData. Test Result Statistics: Summary Data. Available at: http://www.ecstasydata.org/stats.php?style=number&datetype=testingdate&source=ecstasydata [1 August 2013].
22. SaferParty.ch. Website. Available at: www.saferparty.ch [18 December 2013].
23. Checkit! Website. Available at: http://www.checkyourdrugs.at/ [18 December 2013].
24. Trans European Drug Information (TEDI). TEDI Trend Report. Available at: http://www.tediproject.org/uploads/trend_reports_file_1342521771.pdf [15 August 2013].
25. Energy Control. Drug Checking Report 2012. Available at: http://energycontrol.org/files/analisis/Informe_Analisis_ESP_2012.pdf [15 August 2013].
26. O. Corazza, S. Assi, F. Schifano . From 'Special K' to 'Special M': The evolution of the recreational use of ketamine and methoxetamine. CNS Neurosci. Ther. 2013, 19, 454.
27. F. Westphal, T. Junge, U. Girreser, W. Greibl, C. Doering . Mass, NMR and IR spectroscopic characterization of pentedrone and pentylone and identification of their isocathinone by-products. Forensic Sci. Int. 2012, 217, 157.
28. K. Sikk, S. Haldre, S.M. Aquilonius, A. Asser, M. Paris, Ä. Roose, J. Petterson, S.L. Eriksson, J. Berqquist, P. Taba . Manganese-induced parkinsonism in methcathinone abusers: Bio-markers of exposure and follow-up. Eur. J. Neurol. 2013, 20, 915.
29. L. Regan, M. Mitchelson, C. Macdonald . Mephedrone toxicity in a Scottish emergency department. Emerg. Med. J. 2011, 28, 1055.
30. C. Boulanger-Gobeil, M. St-Onge, M. Laliberté, P.L. Auger . Seizures and hyponatremia related to ethcathinone and methylone poisoning. Ann. Emerg. Med. 2012, 60, 103.
31. M.B. Forrester . Synthetic cathinone exposures reported to Texas poison centers. Am. J. Drug Alcohol Abuse 2012, 38, 609.
32. J.M. Prosser, L.S. Nelson . The toxicology of bath salts: A review of synthetic cathinones. J. Med. Toxicol. 2012, 8, 33.
33. B.J. Warrick, J. Wilson, M. Hedge, S. Freeman, K. Leonard, C. Aaron . Lethal serotonin syndrome after methylone and butylone ingestion. J. Med. Toxicol. 2012, 8, 65.
34. Energy Control. Alerta: Pastilla con mezcla de MDMA y metoxetamina (Alert: A pill with a combination of MDMA and methoxetamine). Available at: http://energycontrol.org/analisis-de-sustancias/resultados/alertas/487-alerta-pastilla-con-mezcla-de-mdma-y-metoxetamina.html [20 August 2013].